{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:17:15Z","timestamp":1793312235448,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,11,24]],"date-time":"2010-11-24T00:00:00Z","timestamp":1290556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00280-010-1528-1","type":"journal-article","created":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T12:12:25Z","timestamp":1290514345000},"page":"525-529","source":"Crossref","is-referenced-by-count":15,"title":["Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography\u2013tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity"],"prefix":"10.1007","volume":"68","author":[{"given":"Muhittin A.","family":"Serdar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdim","family":"Serto\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Uyan\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Tapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okhan","family":"Ak\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Cihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,24]]},"reference":[{"key":"1528_CR1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00280-003-0695-8","volume":"52","author":"B Hiroyuki","year":"2003","unstructured":"Hiroyuki B, Kenichi T, Toru K et al (2003) Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol 52:469\u2013476","journal-title":"Cancer Chemother Pharmacol"},{"key":"1528_CR2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/FTD.0b013e3181ae4516","volume":"31","author":"AM Lostia","year":"2009","unstructured":"Lostia AM, Lionetto L, Ialongo C, Gentile G, Viterbo A, Malaguti P, Paris I, Marchetti L, Marchetti P, De Blasi A, Simmaco M (2009) A liquid chromatography\u2013tandem mass spectrometry method for the determination of 5-fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit 31:482\u2013488","journal-title":"Ther Drug Monit"},{"key":"1528_CR3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00535-005-1733-6","volume":"41","author":"K Miyazaki","year":"2006","unstructured":"Miyazaki K, Shibahara T, Sato D et al (2006) Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol 41:140\u2013150","journal-title":"J Gastroenterol"},{"key":"1528_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0378-4347(01)00359-0","volume":"762","author":"R Deporte-Fety","year":"2001","unstructured":"Deporte-Fety R, Picot M, Amiand M et al (2001) High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. J Chromatogr B Biomed Sci Appl 762:203\u2013209","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"1528_CR5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejca.2006.09.017","volume":"43","author":"ABP Kuilenburg Van","year":"2007","unstructured":"Van Kuilenburg ABP, Klumpen HJ, Westermann AM et al (2007) Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. Eur J Cancer 43:459\u2013465","journal-title":"Eur J Cancer"},{"key":"1528_CR6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s002800051022","volume":"45","author":"R Guimbaud","year":"2000","unstructured":"Guimbaud R, Guichard S, Dusseau C et al (2000) Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans. Cancer Chemother Pharmacol 45:477\u2013482","journal-title":"Cancer Chemother Pharmacol"},{"key":"1528_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1081\/CBI-120002597","volume":"19","author":"G Milano","year":"2002","unstructured":"Milano G, Chamorey AL (2002) Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 19:177\u2013189","journal-title":"Chronobiol Int"},{"key":"1528_CR8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/00007691-200210000-00002","volume":"24","author":"A Di Paolo","year":"2002","unstructured":"Di Paolo A, Ibrahim T, Danesi R et al (2002) Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Ther Drug Monit 24:588\u2013593","journal-title":"Ther Drug Monit"},{"key":"1528_CR9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.1998.79","volume":"77","author":"SA Ridge","year":"1998","unstructured":"Ridge SA, Sludden J, Wei X et al (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer 77:497\u2013500","journal-title":"Br J Cancer"},{"key":"1528_CR10","first-page":"5433","volume":"53","author":"ZH Lu","year":"1993","unstructured":"Lu ZH, Zhang RW, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433\u20135438","journal-title":"Cancer Res"},{"key":"1528_CR11","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248\u20132253","journal-title":"J Clin Oncol"},{"key":"1528_CR12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2125.1996.34212.x","volume":"41","author":"J McMurrough","year":"1996","unstructured":"McMurrough J, McLeod HL (1996) Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 41:425\u2013427","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1528_CR13","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","volume":"16","author":"Meta-Analysis Group In Cancer","year":"1998","unstructured":"Meta-Analysis Group In Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16(11):3537\u20133541","journal-title":"J Clin Oncol"},{"key":"1528_CR14","first-page":"2006","volume":"5","author":"MR Johnson","year":"1999","unstructured":"Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006\u20132011","journal-title":"Clin Cancer Res"},{"key":"1528_CR15","first-page":"4705","volume":"6","author":"AB Kuilenburg Van","year":"2000","unstructured":"Van Kuilenburg AB, Haasjes J, Richel DJ et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DHPDH) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DHPDH gene. Clin Cancer Res 6:4705\u20134712","journal-title":"Clin Cancer Res"},{"key":"1528_CR16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10147-003-0330-z","volume":"8","author":"K Omura","year":"2003","unstructured":"Omura K (2003) Clinical implications of dihydropyrimidine dehydrogenase (DHPDH) activity in 5-FU based chemotherapy: mutations in the DHPDH gene, and DHPDH inhibitory fluoropyrimidines. Int J Clin Oncolology 8:132\u2013138","journal-title":"Int J Clin Oncolology"},{"key":"1528_CR17","first-page":"2832","volume":"7","author":"M Raida","year":"2001","unstructured":"Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Hoffken K (2001) Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DHPDH) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7:2832\u20132839","journal-title":"Clin Cancer Res"},{"key":"1528_CR18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0959-8049(97)00345-6","volume":"34","author":"MC Etienne","year":"1998","unstructured":"Etienne MC, Chatelut E, Pivot X et al (1998) Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 34:92\u201397","journal-title":"Eur J Cancer"},{"key":"1528_CR19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.bjc.6690097","volume":"79","author":"AB Kuilenburg Van","year":"1999","unstructured":"Van Kuilenburg AB, van Lenthe H, Blom MJ, Mul EP, Van Gennip AH (1999) Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 79:620\u2013626","journal-title":"Br J Cancer"},{"key":"1528_CR20","first-page":"79","volume":"25","author":"T Furuhata","year":"2006","unstructured":"Furuhata T, Kawakami M, Okita K, Kimura Y, Kihara C, Tsuruma T, Ohnura T, Yamaguchi K, Hata F, Katsuramaki T, Sasaki K, Hirata K (2006) Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients. J Exp Clin Cancer Res 25:79\u201382","journal-title":"J Exp Clin Cancer Res"},{"key":"1528_CR21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","volume":"79","author":"G Milano","year":"1999","unstructured":"Milano G, Etienne MC, Pierrefite V et al (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627\u2013630","journal-title":"Br J Cancer"},{"key":"1528_CR22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265\u2013275","journal-title":"J Biol Chem"},{"key":"1528_CR23","first-page":"197","volume":"50","author":"BE Harris","year":"1990","unstructured":"Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197\u2013201","journal-title":"Cancer Res"},{"key":"1528_CR24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00280-003-0568-1","volume":"51","author":"M Terashima","year":"2003","unstructured":"Terashima M, Irinoda T, Kawamura H et al (2003) Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1\u20135 for gastric cancer, and its pharmacologic and kinetic rationale. Cancer Chemother Pharmacol 51:240\u2013246","journal-title":"Cancer Chemother Pharmacol"},{"key":"1528_CR25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/clinchem\/46.1.9","volume":"46","author":"ABP Kuilenburg Van","year":"2000","unstructured":"Van Kuilenburg ABP, Van Lenthe H, Tromp A et al (2000) Pitfalls in the diagnosis with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 46:9\u201317","journal-title":"Clin Chem"},{"key":"1528_CR26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","volume":"696","author":"MR Johnson","year":"1997","unstructured":"Johnson MR, Yan J, Shao L, Albin N, Diasio RB (1997) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DHPDH) activity. Screening cancer patients for DHPDH deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 696:183\u2013191","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"1528_CR27","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1158\/1078-0432.CCR-05-0217","volume":"11","author":"K Ogura","year":"2005","unstructured":"Ogura K, Ohnuma T, Minamide Y, Mizuno A, Nishiyama T, Nagashima S, Kanomaru M, Hiratsuka A, Watabe T, Uenmatsu T (2005) Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations. Clin Cancer Res 11:5104\u20135111","journal-title":"Clin Cancer Res"},{"key":"1528_CR28","first-page":"395","volume":"3","author":"W Jiang","year":"1997","unstructured":"Jiang W, Lu Z, He Y, Diasio RB (1997) Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3:395\u2013399","journal-title":"Clin Cancer Res"},{"key":"1528_CR29","first-page":"2999","volume":"4","author":"M Kouwaki","year":"1998","unstructured":"Kouwaki M, Hamajima N, Sumi S, Nonaka M, Ssaki M, Dobashi K, Kidouchi K, Togari H, Wada Y (1998) Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-Fluorouracil toxicity. Clin Cancer Res 4:2999\u20133004","journal-title":"Clin Cancer Res"},{"key":"1528_CR30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-1-4615-5381-6_37","volume":"431","author":"S Sumi","year":"1998","unstructured":"Sumi S, Kidouchi K, Hayashi K, Imaeda M, Asai M, Wada Y (1998) Urinary screening for pyrimidine metabolism disorders: reference ranges for dihydrouracil, uracil, and dihydroduracil\/uracil ratio. Adv Exp Med Biol 431:191\u2013195","journal-title":"Adv Exp Med Biol"},{"key":"1528_CR31","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1078-0432.CCR-03-0374","volume":"10","author":"LK Mattison","year":"2004","unstructured":"Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB (2004) Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2\u201313C-uracil breath test. Clin Cancer Res 10:2653\u20132658","journal-title":"Clin Cancer Res"},{"key":"1528_CR32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","volume":"15","author":"LK Mattison","year":"2006","unstructured":"Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB (2006) The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 plasma [2\u201313C] dihydrouracil. Clin Cancer Res 15:549\u2013555","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1528-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1528-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1528-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:33:47Z","timestamp":1636850027000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1528-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,24]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1528-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,24]]}}}